LifeArc has established a successful business model based on forging partnerships. We collaborate with both research groups and pharma and biotech companies to give promising research every chance to succeed. Our independence means we are free to work with the partner most suited to help us deliver new treatments to improve people’s lives.
The Consortium aims to expedite the development of new drugs for dementia by supporting research into novel targets for neurodegeneration. It brings together the voluntary, academic and private sectors in order to tackle the growing dementia problem. The Consortium seeks to end the ten-year wait for a new dementia treatment by closing the gap between fundamental academic research and the pharmaceutical industry’s drug discovery programmes. It provides funding, expertise and resources to support new drug targets emerging from academic research that hold the promise of patient benefit.
Discover the Dementia Consortium
Neurodegeneration Medicines Acceleration Programme
A collection of charities and medical research funders are jointly talking to the pharmaceutical industry to identify stalled, shelved or parked projects which still have the potential to offer new treatments. These projects were paused for strategic, rather than scientific reasons, and through collaboration we could develop potential new treatments to a stage where they are ready for clinical trial and ultimately launch new drugs.
Act Now network
Unless we ACT NOW, promising science is not going to benefit patients. Today’s harsh, commercial reality is that pharmaceutical companies cannot fund every piece of promising research – or even new indications from existing drugs. As a result we don’t have enough new medicines to treat key diseases and medical conditions. We are currently focusing on childhood cancers, rare diseases and antibiotic resistance.
Our team of business development managers are constantly looking for new potential collaborators through research institute visits or at conferences. If you have a project that may be of interest, please contact the team.
Discover the Act Now Network